All News

The use of the chemotherapy ifosfamide was associated with small improvements in survival outcomes in a group of patients with relapsed/refractory Ewing sarcoma, a rare type of bone or soft tissue cancer.

Actress and comedian Jessica St. Clair and her husband, Dan O’Brien, share their roles of partner and parent, but also patient and cancer caregiver, as their roles were reversed in the blink of an eye.

I was approached with the opportunity to ghostwrite for an author who was writing about his cancer journey. I’m still baffled by the timing, but that experience shifted into my eventual cancer journey.

The findings of the study show that Enhertu should be a new standard of care for patients with HER2-low metastatic breast cancer, according to an expert at Memorial Sloan Kettering Cancer Center.

Patients with multiple myeloma were more likely to have no traceable amounts of disease left when Darzalex was added to a treatment regimen of Revlimid, Velcade and dexamethasone.

Survival outcomes and side effect rates were similar in patients with extensive-stage small cell lung cancer who did and did not have tiragolumab added to their treatment regimen of Tecentriq and chemotherapy.

Despite similar responses to treatment, patients with previously treated non-small cell lung cancer derived a better overall survival benefit from treatment with Keytruda combined with Cyramza than the usage of standard-of-care therapies.

Having someone beside you to accompany you during doctor's visits to take notes or having someone to help you find the right specialist or even to just help research what treatment options are available can be incredibly helpful.

At a follow-up of more than two years, treatment with a novel drug produced meaningful results in a group of patients with HER3-expressing metastatic breast cancer or metastatic triple-negative breast cancer.

Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were given Gazyva and chemotherapy.

Treatment with Trodelvy resulted in slight survival improvements, when compared with standard of care chemotherapy regimens, in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Treatment with Lenvima plus Keytruda resulted in a 50% decrease in risk of disease progression or death compared with Sutent in patients with advanced kidney cancer.

Adcetris plus doxorubicin, vinblastine and dacarbazine is the first regimen to improve overall survival compared to the current standard of care for patients with advanced-stage classical Hodgkin lymphoma.

Tibsovo plus Vidaza led to survival benefit for patients with IDH1-mutant acute myeloid leukemia, according to findings from the AGILE clinical trial.

While Cabometyx had a favorable side effect profile, it did not lead to a significant survival advantage over placebo in a clinical trial.

Avasopasem manganese is the first drug that has been shown to reduce the incidence and severity of chemotherapy-related oral mucositis in patients with head and neck cancer, research showed.

Vonjo proved to have a similar, or superior, side effect profile compared with the best available therapy for patients with myelofibrosis, a form of blood cancer.

Adagrasib demonstrated an 80% disease control rate among patients with previously treated KRAS G12C–mutated non–small cell lung cancer.

The addition of nimotuzumab to a treatment regimen of the chemotherapy gemcitabine improved overall survival in patients with KRAS wild-type advanced pancreatic cancer.

Adding Imbruvica to a standard-of-care chemotherapy-immunotherapy treatment regimen was associated with a significant improvement in survival in older patients with newly diagnosed mantle cell lymphoma.

I trusted my oncology team with my life, so it was important that I found doctors I was comfortable with.

From chef Gordon Ramsay sharing a meal with a 13-year-old fan with Ewing sarcoma, to a dermatologist on a playground spotting a mother’s skin cancer, here’s a look at what’s happening in the cancer space this week.

Although she has always been driven to excel, Karen Driskill's, M.S., RN, purpose became more focused after her mother-in-law passed away from intrahepatic cholangiocarcinoma in 2010.

I’m not going to worry that I’m changing my own health by saying out loud that this cancer stuff is hard and scary and kills way too many people every single day.

The Food and Drug Administration granted a fast track designation to PDS0101 plus Keytruda for the treatment of patients with recurrent or metastatic HPV16-related head and neck cancer.

Watching my daughter’s life be interrupted by breast cancer made me want to help other parents who might find themselves in a similar situation.

If approved, Omblastys will be the first FDA-approved drug for children with neuroblastoma that has spread to the central nervous system or leptomeninges.

When I was diagnosed with metastatic breast cancer, my oncology nurse ended up becoming a trusted friend.